A new Website for a Biotech and Pharma Services Partner
March 2026, Regensburg, Germany – 2bind GmbH, a leading contract research organization (CRO) serving the global drug discovery and development sector, today announced the official launch of its newly redesigned corporate website. Following the recent transition of its corporate identity from “Experts in Biophysics” to “Pharma Services,” this digital overhaul ensures that 2bind’s online presence fully reflects its expanded portfolio, modern assay ecosystem, and deep alignment with the biopharma market.
The restructured platform marks the completion of 2bind’s strategic repositioning, translating the company’s physical and scientific evolution into an intuitive, phase-centric digital experience for biotech founders, pharmaceutical developers, and investors worldwide.
Key Facts
- Digital Transformation (March 2026): 2bind launches a fully redesigned corporate website, completing the digital transition to its “Pharma Services” corporate positioning.
- Phase-Centric Framework: The new site maps 2bind’s comprehensive CRO capabilities directly against standard drug discovery and early-stage development phases.
- Molecule-Focused Architecture: Navigation is optimized around therapeutic modalities (Small Molecules, Biologics, Multivalents), moving away from tool-centric descriptions.
- Enhanced Service Visibility: Prominently showcases 2bind’s expanded BSL1/BSL2 cell-based assay ecosystem alongside its foundational biophysical platforms.
Pharma Services: Driven by Molecular Context and Development Phases
While the previous website focused heavily on biophysical methodologies and instruments, the new digital platform shifts the spotlight directly onto the therapeutic molecules themselves and the critical phases of drug discovery and development. This transformation allows users to navigate 2bind’s capabilities based on their specific biological modalities and project maturity.
Key enhancements of the redesigned website include:
- Molecule-Centric Navigation: The platform features dedicated areas tailored to specific molecular modalities, including Small Molecules, Antibodies & Biologics, and specialized areas like Fragment Screening or Proteolysis Targeting Chimeras (PROTACs).
- Clear Alignment with Discovery Phases: Services are now structurally mapped against the standard drug discovery pipeline: from hit identification and validation to early lead selection and developability, enabling clients to instantly locate the exact support needed for their current development stage.
- Highlighting Non-Biophysical Workflows: The website prominently integrates 2bind’s expanded service lines, including its advanced BSL1 and BSL2 cell culture facilities and functional biological and biochemical assays.
For 2bind’s core client base, particularly fast-moving biotech companies looking to maximize pipeline value, the new website serves as an efficient tool to evaluate CRO capabilities. By moving away from tool-centric descriptions and toward a phase-oriented view, the site mirrors the real-world decision-making processes of biotech executives and pharma partners.